• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Serial labeling index determination as a predictor of response in human solid tumors.

作者信息

Murphy W K, Livingston R B, Ruiz V G, Gercovich F G, George S L, Hart J S, Freireich E J

出版信息

Cancer Res. 1975 Jun;35(6):1438-44.

PMID:1093672
Abstract

A rapid method for determining labeling indices in solid tumor specimens, tumor-induced effusions, and tumor-bearing bone marrows was utilized in 116 patients. Of these, 48 patients were studied pre- and postchemotherapy. The magnitude of a significant change in labeling index (LI percent) was determined statistically. Of the 48 patients studied serially, 42 were studied 17 days or less following completion of their chemotherapy. In 26 patients without a significant change in tumor LI percent, there was no subsequent clinical response to chemotherapy. Three additional patients in this group are inevaluable at present. In 11 patients, there was a significant fall in tumor LI percent following chemotherapy. Seven of these had a 50 percent or greater regression of demonstrable disease, one patient had definite tumor effect but the effect was not a partial response and three patients were not evaluable for clinical response. In two patients there was a significant increase in tumor LI percent and the patients had rapid tumor progression and death. Predictions derived from serial study of the LI percent by this method correlate significantly with subsequent behavior of the tumors tested following chemotherapy and may prove clinically useful in making decisions about when or whether to change therapy.

摘要

相似文献

1
Serial labeling index determination as a predictor of response in human solid tumors.
Cancer Res. 1975 Jun;35(6):1438-44.
2
A rapid in vitro labeling index method for predicting response of human solid tumors to chemotherapy.
Cancer Res. 1976 Sep;36(9 pt.1):3279-83.
3
Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.复发侵袭性淋巴瘤的治疗:含与不含高剂量治疗及干细胞救援的方案
Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S13-20. doi: 10.1007/s00280-002-0447-1. Epub 2002 Apr 12.
4
Clinical application of the clonogenic assay.
Ann Clin Lab Sci. 1983 Jan-Feb;13(1):10-5.
5
Correlation of tumor p53 and PCNA with response and survival of glioblastoma in patients treated with an ECOG protocol of pre-irradiation chemotherapy.采用东部肿瘤协作组(ECOG)放疗前化疗方案治疗的胶质母细胞瘤患者中,肿瘤p53和增殖细胞核抗原(PCNA)与疗效及生存的相关性
Clin Neuropathol. 2000 Sep-Oct;19(5):230-4.
6
The potential for complete and durable response in nonglial primary brain tumors in children and young adults with enhanced chemotherapy delivery.通过强化化疗给药,儿童和年轻成人非胶质原发性脑肿瘤实现完全且持久缓解的可能性。
Cancer J Sci Am. 1998 Mar-Apr;4(2):110-24.
7
[Prognostic factors at the cellular level in the treatment of cancer].[癌症治疗中细胞水平的预后因素]
Gan No Rinsho. 1986 Oct;32(13):1715-22.
8
[The effect of the microenvironment of head and neck cancers on tumor progression].[头颈部癌症的微环境对肿瘤进展的影响]
Magy Onkol. 2009 Mar;53(1):51-9. doi: 10.1556/MOnkol.53.2009.1.8.
9
Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts.伊罗氟芬(MGI-114)全身暴露与人类实体瘤异种移植瘤肿瘤反应之间的关系。
Clin Cancer Res. 2002 Sep;8(9):3000-7.
10
p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients.p53免疫染色而非bcl-2免疫染色可预测乳腺癌患者对原发性化疗的临床完全缓解情况不佳。
Clin Cancer Res. 2000 Jul;6(7):2751-8.

引用本文的文献

1
Effects on labeling index as a predictor of response to chemotherapy in the 13762 adenocarcinoma.
Cancer Chemother Pharmacol. 1982 Dec;10(1):47-50. doi: 10.1007/BF00257238.
2
Prediction of response to cancer chemotherapy.
Drugs. 1983 Nov;26(5):454-9. doi: 10.2165/00003495-198326050-00004.
3
[Predictive tumor tests in chemotherapeutic treatment concepts of malignant diseases].
Klin Wochenschr. 1983 Jan 17;61(2):77-84. doi: 10.1007/BF01496658.
4
Sequential assays of hormone receptors and the Tritiated Thymidine Labeling Index in 7,12-dimethylbenz(a)anthracene-induced rat mammary cancers.
Jpn J Surg. 1985 Mar;15(2):150-9. doi: 10.1007/BF02469746.
5
In vitro chemosensitivity testing and its clinical application in human gliomas.体外化学敏感性测试及其在人类胶质瘤中的临床应用。
Neurosurg Rev. 1989;12(3):197-203. doi: 10.1007/BF01743984.
6
Effects of cytotoxic agents on TdR incorporation and growth delay in human colonic tumour xenografts.细胞毒性药物对人结肠肿瘤异种移植中胸苷掺入及生长延迟的影响。
Br J Cancer. 1977 Aug;36(2):206-14. doi: 10.1038/bjc.1977.179.
7
Fractional incorporation of [3H]thymidine and DNA specific activity as assays of inhibition of tumour growth.采用[3H]胸腺嘧啶核苷掺入率和DNA比活性作为肿瘤生长抑制的检测指标。
Br J Cancer. 1977 Jan;35(1):68-77. doi: 10.1038/bjc.1977.5.